Replimune stock.
Is Replimune Stock a Buy? The Bottom Line. Replimune has a lot of potential to treat melanomas and other cancerous tumors. If it's proven effective, it can ...
About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the ...We would like to show you a description here but the site won’t allow us.Replimune Group stock has received a consensus rating of buy. The average rating score is and is based on 21 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Replimune ...Philip Astley-Sparke is a businessperson who founded Replimune Group, Inc. and who has been at the head of 6 different companies. He occupies the position of Chief Executive Officer & Director at Replimune Group, Inc. and Venture Partner at Forbion Capital Partners Management Holding BV. He previously held the position of Chairman at uniQure NV ...
Earnings announcements can affect a stock's price. This table shows the stock's price the day before and the day after recent earnings reports, including the ...The average price recommended by analysts for Replimune Group Inc is $48.44, which is significantly higher than the current market price. This suggests that there is room for the stock price to increase, according to analysts’ predictions. The company has also been involved in the development of a treatment for cutaneous squamous cell ...
BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of …
Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Christopher Sarchi REPL stock SEC Form 4 insiders trading. Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023.. The largest trade Christopher's ever made was selling 5,255 …Replimune remains on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023. As previously announced, this program is intended to include Phase 2 clinical trials in ...Woburn, Massachusetts based Replimune launched its NASDAQ IPO recently, offering 7.4M shares at $15/share, raising $105M.WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed ...
At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies.. Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...
May 18, 2023 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ...
We would like to show you a description here but the site won’t allow us.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Philip Astley-Sparke is a businessperson who founded Replimune Group, Inc. and who has been at the head of 6 different companies. He occupies the position of Chief Executive Officer & Director at Replimune Group, Inc. and Venture Partner at Forbion Capital Partners Management Holding BV. He previously held the position of Chairman at uniQure NV ...Dec 2, 2023 · Replimune Group Inc (REPL) registered a 4.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.74% in intraday trading to $11.71 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is 12.70%, and it has moved by -18.05% in 30 days. Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued. If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.
From the period between 2010 and 2023, Replimune, Working Capital regression line of its data series had standard deviation of 201,967,139 and standard deviation of 201,967,139. Replimune Operating Expenses is quite stable at the moment as compared to the past year. The company's current value of Operating Expenses is estimated at 191.06 Million.A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Replimune is a rapidly growing company, which is exciting to be a part of. There are bonuses, stock options and company outings which make it an appealing company to work for. The company buys lunch at least once a week. Cons. There’s not a lot of stability in day-to-day, week-to-week operations.View the basic REPL option chain and compare options of Replimune Group, Inc. on Yahoo Finance.When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.
Replimune Announces Pricing of Public Offering | Replimune BOSTON , Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group , Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of …8 Des 2022 ... ... Replimune's asset could be the go-to product when anti-PD-1 therapy has failed. The stock closed up 22% yesterday, allowing the group to ...
Get the latest Replimune Group Inc. (REPL) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Nov 23, 2023 · In the past week, REPL stock has gone down by -7.80%, with a monthly decline of -26.02% and a quarterly plunge of -49.58%. The volatility ratio for the week is 8.63%, and the volatility levels for the last 30 days are 9.24% for Replimune Group Inc The simple moving average for the last 20 days […] Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune GroupNovember 29, 2023. $11.32. 786,621. 1:1. $11.67. $11.95. $11.26. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown.View the basic REPL option chain and compare options of Replimune Group, Inc. on Yahoo Finance.Replimune Group, Inc. (REPL) stock forecast and price target. Find the latest Replimune Group, Inc. REPL analyst stock forecast, price target, and recommendation trends with in-depth analysis from ...Dec 3, 2023 · Replimune Group, Inc. ( NASDAQ:REPL – Get Free Report) shares were down 3.4% during trading on Friday . The company traded as low as $10.80 and last traded at $10.80. Approximately 15,578 shares traded hands during trading, a decline of 97% from the average daily volume of 618,826 shares. The stock had previously closed at $11.18. When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i...Replimune story: Replimune Group, Inc. Loses -14.58 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the Corner and other headlines for Replimune GroupOct 15, 2020 · Replimune (NASDAQ: REPL) stock price soared sharply to an all-time high of $46 in Wednesday trading before settling around $36 a share at the end of the session. The shares of the biotechnology company that develops oncolytic immune-gene therapies to treat cancer jumped 46% in Wednesday trading, accelerating twelve months gains to 196%.
Rhumbline Advisers cut its position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 5.2% in the second quarter, according to the …
Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 11.71 +0.53 (+4.74%) At close: 04:00PM EST 11.71 0.00 (0.00%) After hours: 04:20PM EST 1d 5d 1m...
In conclusion, Replimune Group Inc’s stock performance has been buoyed by positive price forecasts from 10 analysts, with a median target price of $50.00. Despite reporting negative earnings per share for the current quarter, investors remain optimistic about the company’s long-term potential.6.68. +0.68. +11.33%. Get Replimune Group Inc (REPL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued.View the latest Replimune Group Inc. (REPL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Replimune Group Inc [REPL] stock prices are up 4.74% to $11.71 at the moment. An important factor to consider is whether the stock is rising or falling in short …Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha's top analysts: exclusive research and insights from bulls and bears.PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …6 brokers have issued 12-month price objectives for Replimune Group's shares. Their REPL share price targets range from $34.00 to $70.00. On average, they anticipate the company's share price to reach $51.33 in the next year. This suggests a possible upside of 353.5% from the stock's current price.Dec 9, 2022 · In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 1,436,172 shares of its common stock from Replimune at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on December 13, 2022, subject to the satisfaction of customary closing conditions. Dec 2, 2023 · Replimune Group Inc (REPL) registered a 4.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.74% in intraday trading to $11.71 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is 12.70%, and it has moved by -18.05% in 30 days. Philip Astley-Sparke is a businessperson who founded Replimune Group, Inc. and who has been at the head of 6 different companies. He occupies the position of Chief Executive Officer & Director at Replimune Group, Inc. and Venture Partner at Forbion Capital Partners Management Holding BV. He previously held the position of Chairman at uniQure NV ...11.32. -0.21. -1.82%. WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio ...
Replimune Group Inc (REPL) Stock Price & News - Google Finance Home REPL • NASDAQ Replimune Group Inc Follow Share $10.39 Nov 24, 5:45:00 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare... Shares of Replimune have lost half of their value since my March 2021 update. Currently, in ROTY we own 8% portfolio weighting with 20% gain. ... The stock could also be impacted by negative ...WOBURN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform ...Instagram:https://instagram. twillo stockhow likely is government shutdownbrian pfeiflernon qualifying mortgage lenders Replimune Group is now considered extended and out of buy range after clearing a 20.23 buy point in a first-stage cup with handle.See if the stock forms a new pattern or follow-on buying ... wall street holidaynewmont mining stocks Also, insider Konstantinos Xynos sold 7,313 shares of Replimune Group stock in a transaction that occurred on Thursday, November 16th. The stock was sold at …All securities in the offering are being offered by Replimune. In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of its common stock from Replimune at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on October … rain industries Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory …BMO Capital Markets raised the price target on Replimune Group Inc (NASDAQ: REPL) to $40 from $30 on a bullish view into upcoming data readouts for lead asset RP1 in melanoma and cutaneous ...